Josep Tabernero

发表

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules

Dimitris Karlis, Xanthi Pedeli, Christoph C Zielinski, 2017, ESMO Open.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Dejan Juric, Jordi Rodon, Alan Huang, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.

Daniel J Sargent, Daniel G Haller, Richard L Schilsky, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

Arijit Chakravarty, Hua Liu, Jeffrey Ecsedy, 2010, Molecular Cancer Therapeutics.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents

Josep Tabernero, J. Tabernero, 2007, Molecular Cancer Research.

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer

Donna Neuberg, Shuji Ogino, Susan Bullman, 2017, Science.

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Keisuke Kuida, Dejan Juric, Serap Sankoh, 2017, Clinical Cancer Research.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Marc Peeters, Yasuhiro Shimada, Ben Tran, 2015, The New England journal of medicine.

EGFR and KRAS in colorectal cancer.

Josep Tabernero, J. Tabernero, B. Markman, 2010, Advances in clinical chemistry.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Patrick Schöffski, Alain C. Mita, Josep Tabernero, 2012, Clinical Cancer Research.

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

Andreas Schlicker, Robert Rosenberg, Victor Moreno, 2013, International journal of cancer.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Sabine Tejpar, Federico Cappuzzo, Mauro Delorenzi, 2010, The Lancet. Oncology.

Aurora kinase family: a new target for anticancer drug.

F. J. Ramos, Josep Tabernero, J. Tabernero, 2008, Recent patents on anti-cancer drug discovery.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Arijit Chakravarty, Hua Liu, Karthik Venkatakrishnan, 2011, Cancer research.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Rodrigo Dienstmann, Josep Tabernero, B. Tops, 2015, Cancer discovery.

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Susan Quinn, Gunnar Folprecht, Josep Tabernero, 2008, Clinical Cancer Research.

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients

Anita Gandhi, Rajesh Chopra, Josep Tabernero, 2013, PloS one.

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

Victor Moreno, Josep Tabernero, Paul Roepman, 2012, Gut.

Unmet needs and challenges in gastric cancer: the way forward.

Fátima Carneiro, Josep Tabernero, William Allum, 2014, Cancer treatment reviews.